Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) presents a significant survival challenge, even in early stages.
• Accurate identification of pathological N0 NSCLC patients who could benefit from adjuvant chemotherapy post-surgery is crucial for improving outcomes.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy in patients with pathological N0 NSCLC after surgical resection.
• To determine if tumor size and differentiation influence the benefit of adjuvant chemotherapy in pN0 NSCLC.

Main Methods:

• Retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results (SEER) database.
• Inclusion of 26,380 patients with pathological N0 NSCLC undergoing surgery (2018-2019).
• 1:1 propensity score matching comparing surgery alone (2107 patients) versus surgery plus adjuvant chemotherapy (2107 patients).

Main Results:

• Adjuvant chemotherapy did not significantly improve 24-month survival in T2aN0 NSCLC (83.41% vs. 82.91%, p=0.067).
• A significant survival benefit was observed for T2bN0 NSCLC patients receiving adjuvant chemotherapy (86.36% vs. 81.70%, p=0.028).
• Poorly differentiated NSCLC was a high-risk factor in pT2N0 stage, with adjuvant chemotherapy showing improved survival post-matching (86.36% vs. 81.70%, p=0.029).

Conclusions:

• Adjuvant chemotherapy demonstrates a beneficial effect in pN0 NSCLC patients with tumor size exceeding 4 cm.
• The impact of adjuvant chemotherapy is less pronounced for tumors between 3 and 4 cm.
• Poorly differentiated histology is a significant risk factor in pT2N0 NSCLC, and adjuvant chemotherapy may improve outcomes in these cases.